---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-22-000011"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:12:03.668045+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex Q1 product revenue $2.10B (+22% YoY); reiterates FY 2022 guidance $8.4-8.6B

## Summary
- Product revenues $2.10B (+22% YoY); TRIKAFTA $1.76B (+48% YoY).
- GAAP diluted EPS $2.96; Non-GAAP diluted EPS $3.52 (up 18% YoY).
- Reaffirmed FY 2022 product revenue guidance $8.4-8.6B.
- Pipeline spans 6 disease areas; positive Phase 2 proof-of-concept studies; more therapies entering clinic H2 2022.
- Changed non-GAAP methodology; no longer exclude certain R&D milestone payments; recast prior periods.

## SEC filing metadata
- accession: 0000875320-22-000011
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532022000011/0000875320-22-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532022000011/vrtx-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-22-000011
- JSON: https://secwatch.observer/filing/0000875320-22-000011.json
- Plain text: https://secwatch.observer/filing/0000875320-22-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.